Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sesen Bio, Inc.

http://www.sesenbio.com/

Latest From Sesen Bio, Inc.

EU Accelerated Assessment Tracker

Novartis is trying its luck with capmatinib on the accelerated assessment front at the European Medicines Agency. Gilead and Astellas/Seagen have secured fast-track review for their respective potential new products while Sesen Bio and Amryt Pharma are dealing with rejection.

Europe Review Pathway

Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Approvals Biosimilars

Janssen Wins EU Fast-Track Status For CAR-T Therapy Cilta-Cel

Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.

Drug Review Review Pathway

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Eleven Biotherapeutics, Inc.
    • Viventia Bio Inc.
UsernamePublicRestriction

Register